Semax has limited human research, mainly in regional stroke and neurological settings. That evidence does not establish reliable cognitive enhancement in healthy people or broad neuroprotective benefits.
Still uncertain: Healthy-person cognitive enhancement, broad neuroprotection, long-term compounded-route safety or an approved regimen.
By confirming your subscription, you agree to receive occasional WhichPeps Evidence Updates. Kit processes the signup and email delivery for WhichPeps. Privacy. Unsubscribe anytime.
What does the evidence mean in simple terms? table
What is it?
ACTH(4-7)-derived synthetic peptide analogue
Entity type
Peptide analogue / modified peptide
Research focus
Stroke/neuroprotection and cognitive research
Human evidence
Older regional stroke and rehabilitation studies report neurological/functional signals and BDNF changes, but this evidence does not establish healthy-person cognitive enhancement.
Regulatory status
Not FDA/EMA-approved; US compounding status has been under FDA review.
Main limitations
Healthy-person cognitive enhancement, broad neuroprotection, long-term compounded-route safety or an approved regimen.
Safety
Safety data outside regional clinical experience are limited; FDA has highlighted insufficient safety information for compounded Semax.
Evidence reviewed
2026-09-18
i
Older regional stroke and rehabilitation studies report neurological/functional signals and BDNF changes, but this evidence does not establish healthy-person cognitive enhancement.
Outcome-level evidence
Evidence is not one score.
Each record below answers a narrower question about an outcome, population or context. Evidence status and the study finding are shown separately so strong evidence is not mistaken for a positive effect.
Safety data outside regional clinical experience are limited; FDA has highlighted insufficient safety information for compounded Semax.
FDA says compounded Semax has no or limited safety information for proposed routes and may pose immunogenicity/impurity risks.
Technical details
Mechanism / biologyProposed neurotrophic/neuroprotective signalling with effects on melanocortin-related and gene-expression pathways.
Route / formulation boundaryDo not convert regional clinical use into a general cognitive-enhancement claim.
Identity / data-quality noteUse the canonical compound identity and studied formulation when interpreting evidence.
Study / label regimen evidenceVerified study/label regimen evidence is available. Published human intranasal research range. Open descriptive regimen evidence →
WhichPeps does not rely on a single headline study when the evidence base is broader. Primary research, registries, regulators and supporting records are kept distinct.
2structured study records
4outcome records
7linked source records
How to read these counts: they show evidence coverage, not evidence strength. One large, well-designed study can be more informative than several weak or indirect records.
Show supporting and discovery sources
Study pages above contain the records used for public evidence summaries. The links below include supporting, regulatory and literature-discovery sources; a registry or search result is not treated as proof of benefit.
PubMed / peer-reviewed source ↗ — Supports contraindication, interaction, monitoring, pregnancy or formulation-safety context in the safety evidence layer.
PubMed / peer-reviewed source ↗ — Historical human evidence reporting intranasal Semax exposure and effects on memory/attention under demanding conditions.
Evidence rule: WhichPeps keeps human, animal, laboratory, regulatory and product/formulation evidence distinct. Common names help people find the page; they do not change the underlying scientific identity.
